Are you suffering from CAPS but still thinking if Anakinra is a better choice for your medical condition? You have landed in the right place. This article deals with an overview of the disease and how Anakinra works and what happens after taking it.
Patients and caregivers researching Kineret Injection in India should discuss the suitability of this treatment with a qualified healthcare professional, particularly when managing a rare autoinflammatory condition such as CAPS.
Understanding CAPS
Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare, inherited autoinflammatory conditions caused by gene mutations that lead to uncontrolled inflammation in the body. It includes three types of conditions from mild to severe in order.
- Familial cold autoinflammatory syndrome (FCAS)
- Muckle-wells syndrome (MWS)
- Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
It is characterised by the periodic episodes of skin rash, fever and joint pain. The triggering factors could be stress, cold temperature and fatigue. It starts from infancy and can trigger throughout your life.
For a broader understanding of the medicine and its mechanism of action, read our guide on Kineret explained: what it is, how it works and who it helps.
Anakinra (Kineret)
In CAPS, abnormal activation of NLRP3 occurs that results in inflammatory cytokine production. An advanced medication named Anakinra treats this condition, not by correcting genetic abnormality but blocks IL-1 receptors leading to reduction of inflammation. It is not limited to treat people with a form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID), but also to treat moderate to severe Rheumatoid Arthritis (RA) and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Avoid Anakinra in patients allergic to proteins made from bacteria called E. coli, or allergic to any of the ingredients in the medication.
The recommended starting dose of Anakinra according to the FDA is 1–2 mg/kg daily for NOMID patients. The dose can be individually adjusted to a maximum of 8 mg/kg daily to control active inflammation. Physicians should consider administration of the prescribed dose every other day for NOMID patients who have severe renal insufficiency or end-stage renal disease (defined as creatinine clearance below 30 mL/min, as estimated from serum creatinine levels).
The most common AEs during the first 6 months of treatment in patients with NOMID are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis.
Patients exploring Kineret Injection in India can also read our guide on Kineret (Anakinra) in India: uses, administration and where to buy for additional information about treatment and access.
Share your medical history to the doctor
Inform your doctor or healthcare provider the following medical conditions:
- If you have infections or past history of infection
- If you have kidney issues
- If you are scheduled to take vaccines
- If you are pregnant
- If you are breastfeeding
Warning signs
Serious infections
Kineret increases the risk of TB or other atypical or opportunistic infections. So, it is essential to treat possible latent tuberculosis infections before starting Anakinra therapy.
Hypersensitivity reactions
Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with Anakinra therapy. Serious cutaneous reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in patients with autoinflammatory conditions treated with this therapy. If a severe hypersensitivity reaction occurs, immediately discontinue KINERET; treat promptly and monitor until signs and symptoms resolve.
Amyloidosis
Post-marketing cases of injection site amyloid deposits have been reported in NOMID patients after receiving high doses of Kineret injected subcutaneously into the same area of skin over long periods of time. Systemic AA amyloidosis occurred in some of these patients with injection site amyloid deposits. It is highly recommended for the patients to rotate their injection sites. In patients with confirmed injection site amyloid deposits, monitor proteinuria for systemic amyloidosis.
Immunizations
No data are available on either the effects of live vaccination or the secondary transmission of infection by live vaccines in patients receiving Anakinra, so it is advised not to take live vaccines concurrently with Anakinra.
Neutrophil count
A decrease in neutrophil count can be observed in patients receiving Anakinra, so it is highly recommended to assess the levels before the commencement of treatment, during treatment, monthly for 3 months, and thereafter quarterly for a period up to 1 year.
Anakinra access, pricing and availability in India
Patients and caregivers looking to Buy Anakinra Injection in India should consult their treating physician and confirm the applicable prescription and import requirements before making arrangements. Access depends on the medicine’s regulatory status and the requirements applicable to the individual request.
For more information about pricing factors and import considerations, read our guide to Anakinra (Kineret) in India: pricing, import guidelines and access options.
The anakinra price in India may vary depending on factors such as product availability, sourcing market, shipping, import-related charges and documentation requirements. Contact the relevant medicine-access provider for current information and an assessment of your requirements.
For further information about sourcing and access considerations, see our Buy Anakinra Injection in India: pricing and supplier guide.
Want the latest medical updates, product details, availability and pricing information? Follow us at 24/7QualityMeds and stay in the loop.
